Institut für Biochemie, Charité - Universitätsmedizin Berlin, Berlin, Germany; Centro Interdipartimentale di Ricerca sul Cancro "Giorgio Prodi,", University of Bologna, Bologna, Italy.
Eur J Immunol. 2014 Dec;44(12):3508-21. doi: 10.1002/eji.201444902. Epub 2014 Nov 20.
Immunoproteasomes are considered to be optimised to process Ags and to alter the peptide repertoire by generating a qualitatively different set of MHC class I epitopes. Whether the immunoproteasome at the biochemical level, influence the quality rather than the quantity of the immuno-genic peptide pool is still unclear. Here, we quantified the cleavage-site usage by human standard- and immunoproteasomes, and proteasomes from immuno-subunit-deficient mice, as well as the peptides generated from model polypeptides. We show in this study that the different proteasome isoforms can exert significant quantitative differences in the cleavage-site usage and MHC class I restricted epitope production. However, independent of the proteasome isoform and substrates studied, no evidence was obtained for the abolishment of the specific cleavage-site usage, or for differences in the quality of the peptides generated. Thus, we conclude that the observed differences in MHC class I restricted Ag presentation between standard- and immunoproteasomes are due to quantitative differences in the proteasome-generated antigenic peptides.
免疫蛋白酶体被认为是优化的,以处理抗原,并通过产生质量不同的 MHC 类 I 表位来改变肽库。免疫蛋白酶体在生化水平上是否影响免疫肽库的质量而不是数量仍不清楚。在这里,我们定量了人类标准和免疫蛋白酶体以及免疫亚单位缺陷小鼠的蛋白酶体的切割位点使用情况,以及从模型多肽产生的肽。我们在这项研究中表明,不同的蛋白酶体同工型在切割位点使用和 MHC 类 I 限制性表位产生方面可以产生显著的定量差异。然而,无论研究的蛋白酶体同工型和底物如何,都没有证据表明特定切割位点使用的消除,或者产生的肽的质量存在差异。因此,我们得出结论,标准和免疫蛋白酶体之间 MHC 类 I 限制性 Ag 呈递的观察到的差异是由于蛋白酶体产生的抗原肽的定量差异。